Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 48-58

  Zhang, Yan ^a   Chen, Kan ^a   Dai, Weiqi ^a   Xia, Yujing ^a   Wang, Fan ^a   Shen, Miao ^a   Cheng, Ping ^a   Wang, Chengfen ^a   Yang, Jing ^a   Zhu, Rong ^b   Zhang, Huawei ^c   Li, Jingjing ^a   Zheng, Yuanyuan ^a   Wang, Junshan ^a   Lu, Jie ^a   Zhou, Yingqun ^a   Guo, Chuanyong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bezafibrate; Meta analysis; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84921023975     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12373     Document Type: Review

References (29)

1. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003; 7: 795-819.
2. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52: 745-758.
3. Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res 2008; 38: 123-131.
4. Corpechot C, Carrat F, Bahr A etal. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303.
5. Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol 2001; 96: 3152-3157.
6. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
7. Nakajima T, Tanaka N, Kanbe H etal. Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol 2009; 75: 782-792.
8. Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology (Baltimore, Md.) 2013; 57: 1691-1693.
9. Iwasaki S, Akisawa N, Saibara T, Onishi S. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 2007; 37: 515-517.
10. Nagasaka H, Yorifuji T, Hirano K etal. Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis. Metabolism 2009; 58: 48-54.
11. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 236963.
12. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
13. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, AlsNielsen B, Colli A. Cochrane Hepato-Biliary Group about the cochrane collaboration (Cochrane Review Groups (CRGs)) 2011; Issue 10. Art. No.: LIVER.
14. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
15. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95: 326-327.
16. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients. J Gastroenterol 2003; 38: 573-578.
17. Itakura J, Izumi N, Nishimura Y etal. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004; 29: 216-222.
18. Iwasaki S, Ohira H, Nishiguchi S etal. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38: 557-564.
19. Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010; 44: 371-373.
20. Takeuchi Y, Ikeda F, Fujioka S etal. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol 2011; 26: 1395-1401.
21. Honda A, Ikegami T, Nakamuta M etal. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology (Baltimore, Md.) 2013; 57: 1931-1941.
22. Kok T, Bloks VW, Wolters H etal. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003; 369: 539-547.
23. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003; 200: 553-560.
24. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 163: 453-459.
25. El-Sisi A, Hegazy S, El-Khateeb E. Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats. PPAR Res 2013; 2013: 781348.
26. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008; 61: 763-769.
27. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64-75.
28. Jie L, Fan W, Weiqi D etal. The hippo-yes association protein pathway in liver cance. Gastroenterol Res Pract 2013; 2013: 187070.
29. Zhou YQ, Dai W, Lin CL etal. Protective effects of necrostatin-1 in concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm 2013; 2013: 706156.